Concerns Over FDA Layoffs and Their Impact on Drug Development

STAT’s FDA reporter Lizzy Lawrence joins to discuss her inside-the-agency reporting on how Robert F. Kennedy Jr. forced top FDA officials to resign at a time when newly sworn-in FDA Commissioner Makary is still figuring out how to get around the agency’s White Oak campus in suburban Maryland. Then: AstraZeneca presented positive mid-stage results this week on a PCSK9 pill that dramatically lowered cholesterol levels on top of traditional statins. R&D executive Sharon Barr joins to talk about why AstraZeneca views this experimental cardiovascular medicine as a key part of its growth strategy.